Maybank Securities is reiterating its "buy" recommendation on Raffles Medical Group (RMG) but with a higher target price of $1.13 from $1.03 previously, given the group's more optimal capital structure. RMG is also the research house's top pick in the Singapore healthcare sector.
Analyst Eric Ong notes that the group has recently signed an agreement with an affiliate of Shanghai Jiao Tong University School of Medicine to work on a new model of collaboration between public hospitals and international medical groups.
The affiliate, Renji Hospital, and RFMD will establish a "dual circulation" medical resource service system, to advance a new model of collaborative development and promote Shanghai as an international medical tourism hub.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.